{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:56:55Z","timestamp":1791863815486,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ELPEN Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11033-020-06089-9","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T22:03:09Z","timestamp":1609711389000},"page":"551-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components"],"prefix":"10.1007","volume":"48","author":[{"given":"Hara","family":"Afaloniati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theofilos","family":"Poutahidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Giakoustidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Gargavanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Giakoustidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-4762","authenticated-orcid":false,"given":"Katerina","family":"Angelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"6089_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"6089_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086","journal-title":"Hepatology"},{"key":"6089_CR3","doi-asserted-by":"publisher","unstructured":"Vogel A, Cervantes A, Chau I et al (2019) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Incidence and epidemiology. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdy308","DOI":"10.1093\/annonc\/mdy308"},{"key":"6089_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","volume":"17","author":"AJ Craig","year":"2020","unstructured":"Craig AJ, von Felden J, Garcia-Lezana T et al (2020) Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 17:139\u2013152","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6089_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ et al (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589\u2013604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6089_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/J.PRP.2017.06.013","volume":"213","author":"ES Chrun","year":"2017","unstructured":"Chrun ES, Modolo F, Daniel FI (2017) Histone modifications: a review about the presence of this epigenetic phenomenon in carcinogenesis. Pathol Res Pract 213:1329\u20131339. https:\/\/doi.org\/10.1016\/J.PRP.2017.06.013","journal-title":"Pathol Res Pract"},{"key":"6089_CR7","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3748\/wjg.v25.i25.3136","volume":"25","author":"D Neureiter","year":"2019","unstructured":"Neureiter D, Stintzing S, Kiesslich T, Ocker M (2019) Hepatocellular carcinoma: therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 25:3136\u20133150. https:\/\/doi.org\/10.3748\/wjg.v25.i25.3136","journal-title":"World J Gastroenterol"},{"key":"6089_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/17474124.2019.1568870","volume":"13","author":"J Zhao","year":"2019","unstructured":"Zhao J, Gray SG, Greene CM, Lawless MW (2019) Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Rev Gastroenterol Hepatol 13:247\u2013256. https:\/\/doi.org\/10.1080\/17474124.2019.1568870","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6089_CR9","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/cancers12113095","volume":"12","author":"S Tapadar","year":"2020","unstructured":"Tapadar S, Fathi S, Wu B et al (2020) Liver-targeting class I selective histone deacetylase inhibitors potently suppress hepatocellular tumor growth as standalone agents. Cancers (Basel) 12:3095. https:\/\/doi.org\/10.3390\/cancers12113095","journal-title":"Cancers (Basel)"},{"key":"6089_CR10","doi-asserted-by":"publisher","first-page":"100167","DOI":"10.1016\/j.jhepr.2020.100167","volume":"2","author":"MG Fern\u00e1ndez-Barrena","year":"2020","unstructured":"Fern\u00e1ndez-Barrena MG, Arechederra M, Colyn L et al (2020) Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep 2:100167. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100167","journal-title":"JHEP Rep"},{"key":"6089_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fgene.2020.578011","volume":"11","author":"L Hontecillas-Prieto","year":"2020","unstructured":"Hontecillas-Prieto L, Flores-Campos R, Silver A et al (2020) Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet 11:1113","journal-title":"Front Genet"},{"key":"6089_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cytogfr.2015.11.009","volume":"27","author":"H Davis","year":"2016","unstructured":"Davis H, Raja E, Miyazono K et al (2016) Mechanisms of action of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 27:81\u201392","journal-title":"Cytokine Growth Factor Rev"},{"key":"6089_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1053\/j.gastro.2012.10.025","volume":"143","author":"M Strazzabosco","year":"2012","unstructured":"Strazzabosco M, Fabris L (2012) Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology 143:1430\u20131434","journal-title":"Gastroenterology"},{"key":"6089_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J (2003) Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell 113:685\u2013700","journal-title":"Cell"},{"key":"6089_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2017.10.002","volume":"8","author":"DH Bach","year":"2018","unstructured":"Bach DH, Park HJ, Lee SK (2018) The dual role of bone morphogenetic proteins in cancer. Mol Ther Oncolytics 8:1\u201313","journal-title":"Mol Ther Oncolytics"},{"key":"6089_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Li D, Feng F et al (2017) Progressive and prognosis value of Notch receptors and ligands in hepatocellular carcinoma: a systematic review and meta-analysis. Sci Rep 7:1\u20139","journal-title":"Sci Rep"},{"key":"6089_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/978-1-4614-0899-4","volume":"727","author":"B Purow","year":"2012","unstructured":"Purow B (2012) Notch signaling in embryology and cancer. Adv Exp Med Biol 727:174\u2013315. https:\/\/doi.org\/10.1007\/978-1-4614-0899-4","journal-title":"Adv Exp Med Biol"},{"key":"6089_CR18","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.2147\/OTT.S250233","volume":"13","author":"H Afaloniati","year":"2020","unstructured":"Afaloniati H, Angelopoulou K, Giakoustidis A et al (2020) HDAC1\/2 inhibitor romidepsin suppresses DEN-induced hepatocellular carcinogenesis in mice. Onco Targets Ther 13:5575\u20135588. https:\/\/doi.org\/10.2147\/OTT.S250233","journal-title":"Onco Targets Ther"},{"key":"6089_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"6089_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.tranon.2014.02.002","volume":"7","author":"E Karamanavi","year":"2014","unstructured":"Karamanavi E, Angelopoulou K, Lavrentiadou S et al (2014) Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol 7:174\u2013187.e5. https:\/\/doi.org\/10.1016\/j.tranon.2014.02.002","journal-title":"Transl Oncol"},{"key":"6089_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043593","volume":"7","author":"Z-S Lin","year":"2012","unstructured":"Lin Z-S, Chu H-C, Yen Y-C et al (2012) Kr\u00fcppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One 7:e43593. https:\/\/doi.org\/10.1371\/journal.pone.0043593","journal-title":"PLoS One"},{"key":"6089_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gene.2017.02.025","volume":"611","author":"AM Ghaleb","year":"2017","unstructured":"Ghaleb AM, Yang VW (2017) Kr\u00fcppel-like factor 4 (KLF4): what we currently know. Gene 611:27\u201337. https:\/\/doi.org\/10.1016\/j.gene.2017.02.025","journal-title":"Gene"},{"key":"6089_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ol.2016.4609","volume":"12","author":"J Lu","year":"2016","unstructured":"Lu J, Xia Y, Chen K et al (2016) Oncogenic role of the notch pathway in primary liver cancer. Oncol Lett 12:3\u201310","journal-title":"Oncol Lett"},{"key":"6089_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.28509","volume":"64","author":"C Liu","year":"2016","unstructured":"Liu C, Liu L, Chen X et al (2016) Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology 64:117\u2013129. https:\/\/doi.org\/10.1002\/hep.28509","journal-title":"Hepatology"},{"key":"6089_CR25","doi-asserted-by":"publisher","first-page":"23058","DOI":"10.18632\/oncotarget.5492","volume":"6","author":"RV Sionov","year":"2015","unstructured":"Sionov RV, Vlahopoulos SA, Granot Z (2015) Regulation of Bim in health and disease. Oncotarget 6:23058\u201323134. https:\/\/doi.org\/10.18632\/oncotarget.5492","journal-title":"Oncotarget"},{"key":"6089_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-0676.2001.021002089.x","volume":"21","author":"M Joo","year":"2001","unstructured":"Joo M, Kang YK, Kim MR et al (2001) Cyclin D1 overexpression in hepatocellular carcinoma. Liver 21:89\u201395. https:\/\/doi.org\/10.1034\/j.1600-0676.2001.021002089.x","journal-title":"Liver"},{"key":"6089_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1369\/0022155413479123","volume":"61","author":"\u00c1 Holczbauer","year":"2013","unstructured":"Holczbauer \u00c1, Gy\u00f6ngy\u00f6si B, Lotz G et al (2013) Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas. J Histochem Cytochem 61:294\u2013305. https:\/\/doi.org\/10.1369\/0022155413479123","journal-title":"J Histochem Cytochem"},{"key":"6089_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/ijc.27964","volume":"132","author":"LSH Chuang","year":"2013","unstructured":"Chuang LSH, Ito K, Ito Y (2013) RUNX family: regulation and diversification of roles through interacting proteins. Int J Cancer 132:1260\u20131271. https:\/\/doi.org\/10.1002\/ijc.27964","journal-title":"Int J Cancer"},{"key":"6089_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1440-169X.2005.00821.x","volume":"47","author":"D Sakai","year":"2005","unstructured":"Sakai D, Tanaka Y, Endo Y et al (2005) Regulation of Slug transcription in embryonic ectoderm by \u03b2-catenin-Lef\/Tcf and BMP-Smad signaling. Develop Growth Differ 47:471\u2013482. https:\/\/doi.org\/10.1111\/j.1440-169X.2005.00821.x","journal-title":"Develop Growth Differ"},{"key":"6089_CR30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jcp.20304","volume":"204","author":"K Pardali","year":"2005","unstructured":"Pardali K, Kowanetz M, Heldin CH, Moustakas A (2005) Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21WAF1\/Cip1. J Cell Physiol 204:260\u2013272. https:\/\/doi.org\/10.1002\/jcp.20304","journal-title":"J Cell Physiol"},{"key":"6089_CR31","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.3748\/wjg.v21.i42.12150","volume":"21","author":"S Ohkoshi","year":"2015","unstructured":"Ohkoshi S, Yano M, Matsuda Y (2015) Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 21:12150. https:\/\/doi.org\/10.3748\/wjg.v21.i42.12150","journal-title":"World J Gastroenterol"},{"key":"6089_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A (2009) P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400\u2013414","journal-title":"Nat Rev Cancer"},{"key":"6089_CR33","volume-title":"p21: a two-faced genome guardian","author":"AG Georgakilas","year":"2017","unstructured":"Georgakilas AG, Martin OA, Bonner WM (2017) p21: a two-faced genome guardian. Elsevier Ltd, Amsterdam"},{"key":"6089_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.suronc.2018.07.015","volume":"27","author":"DI Tsilimigras","year":"2018","unstructured":"Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D et al (2018) Histone deacetylase inhibitors in hepatocellular carcinoma: a therapeutic perspective. Surg Oncol 27:611\u2013618. https:\/\/doi.org\/10.1016\/j.suronc.2018.07.015","journal-title":"Surg Oncol"},{"key":"6089_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bcp.2016.12.008","volume":"127","author":"W-J Sun","year":"2017","unstructured":"Sun W-J, Huang H, He B et al (2017) Romidepsin induces G2\/M phase arrest via Erk\/cdc25C\/cdc2\/cyclinB pathway and apoptosis induction through JNK\/c-Jun\/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol 127:90\u2013100","journal-title":"Biochem Pharmacol"},{"key":"6089_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12447","volume":"51","author":"H Zhou","year":"2018","unstructured":"Zhou H, Cai Y, Liu D et al (2018) Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1\/Cip1 and p19INK4d upregulation in hepatocellular carcinoma. Cell Prolif 51:e12447. https:\/\/doi.org\/10.1111\/cpr.12447","journal-title":"Cell Prolif"},{"key":"6089_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2020.00194","volume":"10","author":"G Wu","year":"2020","unstructured":"Wu G, Huang F, Chen Y et al (2020) High levels of BMP2 promote liver cancer growth via the activation of myeloid-derived suppressor cells. Front Oncol 10:194. https:\/\/doi.org\/10.3389\/fonc.2020.00194","journal-title":"Front Oncol"},{"key":"6089_CR38","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1007\/s13277-014-1673-y","volume":"35","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, Wang X, Wang H et al (2014) Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K\/AKT pathway. Tumor Biol 35:5189\u20135198. https:\/\/doi.org\/10.1007\/s13277-014-1673-y","journal-title":"Tumor Biol"},{"key":"6089_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s13277-012-0594-x","volume":"34","author":"W Li","year":"2013","unstructured":"Li W, Cai HX, Ge XM et al (2013) Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma. Tumor Biol 34:669\u2013674. https:\/\/doi.org\/10.1007\/s13277-012-0594-x","journal-title":"Tumor Biol"},{"key":"6089_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yexmp.2011.10.004","volume":"92","author":"U Maegdefrau","year":"2012","unstructured":"Maegdefrau U, Bosserhoff AK (2012) BMP activated Smad signaling strongly promotes migration and invasion of hepatocellular carcinoma cells. Exp Mol Pathol 92:74\u201381. https:\/\/doi.org\/10.1016\/j.yexmp.2011.10.004","journal-title":"Exp Mol Pathol"},{"key":"6089_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2018.00295","volume":"8","author":"P Koganti","year":"2018","unstructured":"Koganti P, Levy-Cohen G, Blank M (2018) Smurfs in protein homeostasis, signaling, and cancer. Front Oncol 8:295","journal-title":"Front Oncol"},{"key":"6089_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.mce.2010.10.019","volume":"332","author":"CC Ho","year":"2011","unstructured":"Ho CC, Zhou X, Mishina Y, Bernard DJ (2011) Mechanisms of bone morphogenetic protein 2 (BMP2) stimulated inhibitor of DNA binding 3 (Id3) transcription. Mol Cell Endocrinol 332:242\u2013252. https:\/\/doi.org\/10.1016\/j.mce.2010.10.019","journal-title":"Mol Cell Endocrinol"},{"key":"6089_CR43","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1038\/sj.onc.1205093","volume":"20","author":"A Lasorella","year":"2001","unstructured":"Lasorella A, Uo T, Iavarone A (2001) Id proteins at the cross-road of development and cancer. Oncogene 20:8326\u20138333. https:\/\/doi.org\/10.1038\/sj.onc.1205093","journal-title":"Oncogene"},{"key":"6089_CR44","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/j.1474-9726.2011.00746.x","volume":"10","author":"Y Kong","year":"2011","unstructured":"Kong Y, Cui H, Zhang H (2011) Smurf2-mediated ubiquitination and degradation of Id1 regulates p16 expression during senescence. Aging Cell 10:1038\u20131046. https:\/\/doi.org\/10.1111\/j.1474-9726.2011.00746.x","journal-title":"Aging Cell"},{"key":"6089_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hep.20571","volume":"41","author":"A Croquelois","year":"2005","unstructured":"Croquelois A, Blindenbacher A, Terracciano L et al (2005) Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 41:487\u2013496. https:\/\/doi.org\/10.1002\/hep.20571","journal-title":"Hepatology"},{"key":"6089_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15384047.2015.1016662","volume":"16","author":"ZH Liu","year":"2015","unstructured":"Liu ZH, Dai XM, Du B (2015) Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther 16:353\u2013359","journal-title":"Cancer Biol Ther"},{"key":"6089_CR47","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.3390\/ijms15069894","volume":"15","author":"H-T Hsu","year":"2014","unstructured":"Hsu H-T, Wu P-R, Chen C-J et al (2014) High cytoplasmic expression of Kr\u00fcppel-like factor 4 is an independent prognostic factor of better survival in hepatocellular carcinoma. Int J Mol Sci 15:9894\u20139906. https:\/\/doi.org\/10.3390\/ijms15069894","journal-title":"Int J Mol Sci"},{"key":"6089_CR48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc3582","volume":"13","author":"MP Tetreault","year":"2013","unstructured":"Tetreault MP, Yang Y, Katz JP (2013) Kr\u00fcppel-like factors in cancer. Nat Rev Cancer 13:701\u2013713","journal-title":"Nat Rev Cancer"},{"key":"6089_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1746-1596-7-44","volume":"7","author":"X Guo","year":"2012","unstructured":"Guo X, Xiong L, Sun T et al (2012) Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 7:44. https:\/\/doi.org\/10.1186\/1746-1596-7-44","journal-title":"Diagn Pathol"},{"key":"6089_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.onc.1202409","volume":"18","author":"A Suzuki","year":"1999","unstructured":"Suzuki A, Tsutomi Y, Miura M, Akahane K (1999) Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18:1239\u20131244. https:\/\/doi.org\/10.1038\/sj.onc.1202409","journal-title":"Oncogene"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-06089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-020-06089-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-06089-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T17:57:50Z","timestamp":1646416670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-020-06089-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["6089"],"URL":"https:\/\/doi.org\/10.1007\/s11033-020-06089-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval and licensing (License reference no 4956\/09-08-2012) were provided by the competent National Veterinary Administration Authorities according to Greek legislative (Decree no. 2015\/92, 160\/91) and European Communities Council directive (no. 86\/609\/EEC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors consent for participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}